This session examines the current landscape and promising future of theranostics, from three distinct but equally important vantage points: The clinician, the radiochemist and the manufacturer. Understanding the interdependencies of these stakeholders will help ensure the value of this critical modality for patients now and well into the future.
For more information or to register click here:
Session Moderator
General Manager, ITM USA
Current and Future Utilization of Theranostics: A Clinical Perspective
Chief Medical Advisor, BAMF Health
Synergy Between Lu-177 & Ac-225: A Radiochemistry Perspective
M.Sc, Product Management Radionuclides, ITM
Commercial Availability of Ac-225: A Technology Perspective
M.Sc., MBA, VP-Canadian National Laboratories
Session Moderator
General Manager, ITM USA
Current and Future Utilization of Theranostics: A Clinical Perspective
Chief Medical Advisor, BAMF Health
Synergy Between Lu-177 & Ac-225: A Radiochemistry Perspective
M.Sc, Product Management Radionuclides, ITM
Commercial Availability of Ac-225: A Technology Perspective
M.Sc., MBA, VP-Canadian National Laboratories
ITM Isotope Technologies Munich SE
Lichtenbergstrasse 1
85748 Garching / Munich, Germany
Email: info(at)itm-radiopharma.com
Phone: +49 89 329 8986 6000
Fax: +49 89 329 8986 6061
